In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Quarterly Statistics Q1 2010

Executive Summary

In Vivo presents another quarterly review of pharmaceutical/biotechnology dealmaking - for the first quarter of 2010. Our data come from Elsevier's Strategic Transactions. During the first quarter of 2010, biopharma companies raised $2.6 billion through 94 transactions, slightly better than last year's opening, but a decrease of 43% from Q4 2009. Early venture capital rounds were the most popular type of financings, followed closely by follow-on public offerings and private investments in public companies, but FOPOs clearly brought in the most money, $1.1 billion.With less than half the M&A deal volume of the previous quarter - however, about the same dollar figure - Q1 2010's 12 transactions brought in $7.1 billion.
Advertisement

Related Content

Biotech Backers Learn To Live With Exit-By-Earn-Out
Teva Wins ratiopharm, As it Moves to Solidify its EU Position
Teva Wins ratiopharm, As it Moves to Solidify its EU Position
Anthera Takes A "Haircut" And Delays Its Planned Initial Stock Offering
Capital Markets Open To Health Care, But Just A Crack, Panelists Say
Is Ironwood The IPO Medicine To Get Things Moving?
Teva's Growth Strategy In Europe: Bullish on Germany (Part 1 of 2)
Teva's Growth Story
Novartis Eyes Full, $50 billion Alcon Takeover
Novartis Eyes Full, $50 billion Alcon Takeover

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel